

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/753,261
		Filing Date	January 7, 2004
		First Named Inventor	Daun
		Group Art Unit	1625
Examiner Name	Amelia Owens		
Sheet	1	of	1
		Attorney Docket Number	9626.9IPX

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
/R.D./		US- 4,877,810	10-31-1989	Mickle et al.	
		US- 4,939,146	07-02-1990	Kramer et al.	
		US- 4,999,365	03-12-1991	Dage et al.	
		US- 5,002,965	03-26-1991	Ramwell et al.	
		US- 5,618,785	04-08-1997	Heavner et al.	
		US- 5,632,991	05-27-1997	Gimbrone, Jr.	
		US- 5,728,685	03-17-1998	Abbas et al.	
		US- 6,048,841	04-11-2000	Baxter et al.	
		US- 6,110,967	08-29-2000	Asao et al.	claims 21-23
		US- 6,358,978 B1	03-19-2002	Ritzeler et al.	
		US- 6,608,072 B1	08-19-2003	Révész	
		US- 6,693,108 B2	02-17-2004	Green et al.	claim 11
		US- 6,747,053 B2	06-08-2004	Gabriel et al.	claim 36
		US- 6,884,804 B2	04-26-2005	Choon-Moon	claim 24
/R.D./		US- 7,186,683 B2	03-06-2004	Henriksen et al.	claim 3

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code Number Kind Code (if known)				
/R.D./		EP 1 224 185 B1	11-30-2005	Novartis AG		
/R.D./		EP 1 194 425 B1	01-04-2001	Aventis Pharma Deutschland GmbH		
/R.D./		AU 2001112728 B2	08-05-2001	Aventis Pharma Deutschland GmbH		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
/R.D./		International Search Report for corresponding International Application PCT/US/2004/00293 (WO 2004/063336 A3) (07-29-2004)	
/R.D./		HAKOMORI, S, Tumor Malignancy Defined by Aberrant Glycosylation and Sphingo(glycol)lipid Metabolism, Cancer Research (December 1, 1996) pp 5309-5318, vol 56	
/R.D./		DIMITROFF, C J, et al., Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells, Cancer Res 2005 (July 1, 2005) pp 5750-5760, vol 65:13, www.aacrjournals.org	

iDoc# 572822

Examiner Signature	/Rita Desai/	Date Considered	07/09/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.